A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease

Abdullah Kutlar, Marvin E. Reid, Adlette Inati, Ali T. Taher, Miguel R. Abboud, Amal El-Beshlawy, George R. Buchanan, Hedy Smith, Kenneth I. Ataga, Susan P. Perrine, Richard G. Ghalie

Research output: Contribution to journalArticle

21 Scopus citations

Fingerprint Dive into the research topics of 'A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease'. Together they form a unique fingerprint.

Medicine & Life Sciences